A low-protein longevity diet supplemented with methionine (LDMM) — modeled on traditional Mediterranean and Okinawan eating patterns — outperformed western and ketogenic diets across multiple healthspan metrics in mice. LDMM reduced fat mass, frailty, and IGF-1 while simultaneously elevating growth hormone, GLP-1, and FGF21. FGF21 was specifically required for both fat loss and improved insulin sensitivity. An epidemiological cross-section of over 200,000 individuals found the highest animal-protein consumers had roughly double the prevalence of type 2 diabetes versus the lowest consumers, despite otherwise healthier lifestyle profiles.
This finding is noteworthy because it resolves a persistent tension in longevity nutrition: low-protein diets suppress IGF-1 favorably but risk accelerating sarcopenia and frailty in aging adults. The LDMM approach threads that needle by preserving methionine — a sulfur amino acid critical for muscle protein synthesis and methylation reactions — while keeping overall amino acid load low enough to activate FGF21-mediated metabolic benefits. The GLP-1 elevation is particularly striking given current pharmaceutical enthusiasm for GLP-1 agonists; achieving dietary GLP-1 upregulation without drugs would have enormous clinical relevance. Limitations are significant: the mechanistic data are mouse-derived, and the human epidemiological arm is observational and cross-sectional, incapable of establishing causality. The confounding of healthy-lifestyle behaviors among high-protein consumers also warrants caution. Still, this is a conceptually important, paradigm-nudging study that refines the protein-restriction longevity framework with actionable dietary specificity.
